We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Gene Discovered that Inhibits Tumor Growth in Multiple Cancers

By Biotechdaily staff writers
Posted on 27 Aug 2007
Investigators have found a novel gene that suppresses the growth of human tumors in multiple cancers, including breast, lung, and liver cancers, in addition to melanomas, lymphomas, and sarcomas. More...

Published in the August 12, 2007, advance online publication of the journal Nature Medicine, the study found that a gene, HACE1, has the ability to help cells tackle various forms of stress, including environmental cancer triggers that cause tumor formation. When the HACE1 gene is missing or inactive, cancerous cells are able to form tumors, and when the gene is re-expressed, it prevents these cells from forming tumors.

The study was conducted in collaboration with Dr. Josef Penninger, from the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA; Vienna). "The discovery of this gene is very exciting because it clearly impacts a wide range of cancers, and provides a novel link between cellular stress and cancer,” stated Dr. Poul Sorensen, senior scientist at the BC Cancer Agency (Canada), an agency of the Canadian Provincial Health Services Authority. "If we can learn how to reactivate HACE1 or block cancer cells from inactivating this gene, it may be possible to improve treatments for many cancer patients.”

To assess whether HACE1 is a tumor-suppressor gene, researchers knocked out the gene in laboratory mice. They theorized that the mice would be more susceptible to tumor growth, and diverse tumors did indeed form but at a low rate. However, when the mice were also subjected to various forms of stress, including ultraviolet radiation, lung carcinogens, or other genetic changes, this resulted in a drastic increase in cancer growth, with the mice developing breast, lung, and liver cancers, as well as lymphomas, melanomas, and sarcomas.

Researchers also re-introduced the HACE1 gene into human tumor cells and discovered that cells lost their ability to form tumors. On the other hand, when levels of HACE1 were experimentally reduced in non-cancerous cells, they were able to form tumors. "We've always suspected that cancer is caused by a combination of genetic and environmental factors working together,” stated Dr. Sorensen. "Our results give us insight into how the disease takes root when a single gene is inactivated.”

The next phase of the research, according to the investigators, will be to evaluate the biologic mechanism that enables HACE1 to deal with cancer stress and block tumor formation.


Related Links:
BC Cancer Agency
Institute of Molecular Biotechnology of the Austrian Academy of Sciences

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.